REGENXBIO Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
RGNX$7.69-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net income (loss) | $(263,494) | $(280,321) | $127,840 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | |||
| Stock-based compensation expense | 40,267 | 40,788 | 38,808 |
| Depreciation and amortization | 17,320 | 12,909 | 9,564 |
| Provision for credit losses (recoveries) | — | — | (2,569) |
| Net amortization of premiums on marketable debt securities | 687 | 4,712 | 5,842 |
| Net realized loss (gain) on investments | (2,205) | 79 | (5,189) |
| Non-cash interest expense | (414) | 137 | 4,642 |
| Other non-cash adjustments | 319 | 231 | (281) |
| Changes in operating assets and liabilities | |||
| Accounts receivable | 3,935 | 4,822 | 14,118 |
| Prepaid expenses | (620) | 4,852 | (8,247) |
| Other current assets | (10,546) | 247 | (7,314) |
| Operating lease right-of-use assets | 5,761 | 4,450 | 4,866 |
| Other assets | 1,590 | 31 | (2,272) |
| Accounts payable | (2,791) | 18,790 | (2,304) |
| Accrued expenses and other current liabilities | 2,452 | (25,616) | 29,908 |
| Deferred revenue | (1,512) | (1,165) | (899) |
| Operating lease liabilities | (6,641) | (544) | 12,073 |
| Other liabilities | (2,515) | 8,110 | 289 |
| Net cash provided by (used in) operating activities | (218,407) | (207,488) | 218,875 |
| Cash flows from investing activities | |||
| Purchases of marketable debt securities | (86,564) | (184,875) | (498,144) |
| Maturities of marketable debt securities | 285,492 | 203,146 | 170,086 |
| Sales of equity securities | 1,975 | 524 | 5,591 |
| Purchases of property and equipment | (9,960) | (30,724) | (84,175) |
| Net cash provided by (used in) investing activities | 190,943 | (11,929) | (406,642) |
| Cash flows from financing activities | |||
| Proceeds from exercise of stock options | 1,521 | 2,804 | 4,281 |
| Taxes paid related to net settlement of stock-based awards | (419) | (284) | (2) |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,826 | 1,742 | 1,768 |
| Proceeds from public offering of common stock, net of underwriting discounts and commissions | — | — | 216,438 |
| Proceeds from private placement of common stock, net of issuance costs | 4,874 | — | — |
| Offering expenses related to at-the-market offering program | (470) | — | — |
| Issuance costs for public offering of common stock | — | — | (379) |
| Transaction costs for sale of future royalties | — | — | (265) |
| Repayments under liability related to sale of future royalties, net of imputed interest | (42,298) | (33,102) | (26,591) |
| Net cash provided by (used in) financing activities | (34,966) | (28,840) | 195,250 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | (62,430) | (248,257) | 7,483 |
| Cash and cash equivalents and restricted cash | |||
| Beginning of period | 98,982 | 347,239 | 339,756 |
| End of period | $36,552 | $98,982 | $347,239 |
| Supplemental cash flow information | |||
| Cash paid (received) for income taxes | $(142) | $11,812 | $5,996 |
| Cash paid for imputed interest under liability related to sale of future royalties | $7,276 | $23,117 | $21,635 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.